I stumbled upon this and thought that some people may be interested in this research study. It's at Beth Israel Hospital in NYC.
http://clinicaltrials.gov/ct2/show/NCT00668265
Anxiety in Recovering Opiate Dependence
This study is currently recruiting participants.
Verified by Beth Israel Medical Center, February 2009
First Received: April 28, 2008 Last Updated: February 20, 2009 History of Changes
Sponsors and Collaborators: Beth Israel Medical Center
AstraZeneca
Information provided by: Beth Israel Medical Center
ClinicalTrials.gov Identifier: NCT00668265
Purpose
This is a 16 week study of the efficacy of quetiapine in treating symptoms of generalized anxiety disorder (GAD) in subjects with comorbid opiate dependence. The study will be conducted in a prospective, randomized, double-blind, and placebo-controlled fashion. Study subjects will be inpatients at a residential drug-treatment facility, enrolled in a 1 year methadone-to-abstinence treatment plan. Subjects will be randomized to receive either quetiapine or placebo in addition to ongoing drug addiction treatment. Subjects will be followed for 16 weeks and a variety of psychometric assessments will be made. Hypothesis One: Compared to placebo, Quetiapine will demonstrate a greater reduction in symptoms of anxiety in subjects with GAD and remitted comorbid opiate abuse. Exploratory Hypotheses: Compared to placebo, Quetiapine will demonstrate a greater improvement in psychosocial functioning and compliance with community norms in subjects enrolled in a residential drug addiction treatment facility.
http://clinicaltrials.gov/ct2/show/NCT00668265
Anxiety in Recovering Opiate Dependence
This study is currently recruiting participants.
Verified by Beth Israel Medical Center, February 2009
First Received: April 28, 2008 Last Updated: February 20, 2009 History of Changes
Sponsors and Collaborators: Beth Israel Medical Center
AstraZeneca
Information provided by: Beth Israel Medical Center
ClinicalTrials.gov Identifier: NCT00668265
Purpose
This is a 16 week study of the efficacy of quetiapine in treating symptoms of generalized anxiety disorder (GAD) in subjects with comorbid opiate dependence. The study will be conducted in a prospective, randomized, double-blind, and placebo-controlled fashion. Study subjects will be inpatients at a residential drug-treatment facility, enrolled in a 1 year methadone-to-abstinence treatment plan. Subjects will be randomized to receive either quetiapine or placebo in addition to ongoing drug addiction treatment. Subjects will be followed for 16 weeks and a variety of psychometric assessments will be made. Hypothesis One: Compared to placebo, Quetiapine will demonstrate a greater reduction in symptoms of anxiety in subjects with GAD and remitted comorbid opiate abuse. Exploratory Hypotheses: Compared to placebo, Quetiapine will demonstrate a greater improvement in psychosocial functioning and compliance with community norms in subjects enrolled in a residential drug addiction treatment facility.
Last edited by a moderator: